Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

Required: SSTR2 overexpression (uptake at least as high as liver in at least one target lesion)

[68Ga]Ga-DOTATATE uptake on PET-CT. Positive uptake is defined as uptake at least as high as liver, based on the uptake in at least one target lesion.

Cannot have received: SSTR2-targeted therapy (Somatostatin LAR, short-acting Octreotide)

Prior SSTR2-targeted therapy, e.g. Somatostatin LAR or short-acting Octreotide

Cannot have received: peptide receptor radionuclide therapy

Peptide receptor radionuclide therapy at any time prior to registration.

Cannot have received: cytotoxic chemotherapy

Exception: 28 days (or 5 half-lives, whichever is longer) prior to step 2 registration

28 days (or 5 half-lives, whichever is longer) for cytotoxic chemotherapy, biologic agent, investigational agent or any other systemic agent prescribed for the purpose of treating meningioma

Cannot have received: nitrosoureas

Exception: 6 weeks prior to step 2 registration

6 weeks from nitrosoureas

Cannot have received: external beam radiation, interstitial brachytherapy or stereotactic radiosurgery

Exception: cumulative radiation dose of > 70 Gy or the last dose of radiotherapy < 24 weeks (6 months) prior to step 2 registration

Prior external beam radiation, interstitial brachytherapy or stereotactic radiosurgery cumulative radiation dose of > 70 Gy or the last dose of radiotherapy < 24 weeks (6 months) prior to step 2 registration